Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

AMYLYX PHARMACEUTICALS INC (AMLX)

170 + Investors. Track Smart Money conviction in AMLX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -8
Streak
1Q ▼
Buyers last Q
50%

Smart Money Signals — AMLX

Based on 171 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their AMLX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
171 hedge funds hold AMLX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+35 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 50% buying

91 buying90 selling
Last quarter: 91 funds bought or added vs 90 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-14 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 30 → 57 → 40 → 26. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 29% medium ■ 28% new
73 out of 171 hedge funds have held AMLX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

31 → 30 → 57 → 40 → 26 new funds/Q
New funds entering each quarter: 30 → 57 → 40 → 26. AMLX is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Deep conviction — 58% of holders stayed 2+ years

■ 58% veterans ■ 11% 1-2yr ■ 32% new
Of 180 current holders: 104 (58%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds
39 of 171 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — AMLX

In 2026 Q1, 91 hedge funds were net buyers of AMLX (26 opened a new position, 65 added to an existing one), while 90 reduced or exited (56 trimmed, 34 sold completely) — a 50% buyer ratio, indicating a slight buying edge. 37% of total institutional value in AMLX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -8 funds (more exits than new entries). Total institutional holders: 171.

Hedge Fund Ownership: AMLX

How many hedge funds hold AMLX — quarterly history vs. share price
Quarterly hedge fund ownership of AMLX vs. share price

Market Analysis: AMLX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AMLX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy AMYLYX PHARMACEUTICALS INC (AMLX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AMLX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 71d ago
AMLX
-6.0%
XLV
+4.1%

AMLX outperformed XLV by -10.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 26d ago
AMLX
-2.1%
XLV
+5.2%

Since the filing became public, AMLX outperformed XLV by -7.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

20 top-rated funds 3 high-conviction
Consensus
5.7
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: AMLX
170 + Investors

Track Smart Money conviction in AMLX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 170 179 -5.03%
13F Shares 115M 113M 1.87%
Total Value $1.59B $1.36B 16.83%
New Positions 25 40 -15
Increased Positions 64 72 -8
Closed Positions 34 31 +3
Reduced Positions 52 44 +8
Total Calls 6 6 -
Total Puts 5 5 -
PUT/CALL Ratio 0.83 0.83 Neutral

Statistics: AMLX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

170 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AMLX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 institutional holders of AMLX — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Saturn V Capital Management LP 10.95% 4,349,885 $60.5M
2 Almitas Capital LLC 6.67% 2,122,597 $29.5M
3 GREAT POINT PARTNERS LLC 5.59% 1,750,000 $24.3M
4 Jones Hill Capital LP 4.76% 1,598,794 $22.2M
5 Commodore Capital LP 4.54% 5,650,000 $78.5M
6 First Light Asset Management, LLC 3.97% 3,190,645 $44.3M
7 TCG Crossover Management, LLC 2.48% 6,243,812 $86.8M
8 PERCEPTIVE ADVISORS LLC 2.25% 8,284,882 $115.2M
9 Aldebaran Capital, LLC 2.10% 197,892 $2.8M
10 STEMPOINT CAPITAL LP 1.81% 669,685 $9.3M
11 ACUTA CAPITAL PARTNERS, LLC 1.48% 151,067 $2.1M
12 Boxer Capital Management, LLC 1.46% 800,000 $11.1M
13 HighVista Strategies LLC 1.35% 352,085 $4.9M
14 683 Capital Management, LLC 1.11% 1,530,000 $21.3M
15 Parkman Healthcare Partners LLC 0.89% 621,458 $8.6M
16 Tetragon Partners GP Ltd 0.86% 317,877 $4.4M
17 ADAR1 Capital Management, LLC 0.82% 1,000,604 $13.9M
18 Logos Global Management LP 0.49% 700,000 $9.7M
19 Siren, L.L.C. 0.47% 1,230,000 $17.1M
20 Elmind Capital, LP 0.44% 112,000 $1.6M
21 Rock Springs Capital Management LP 0.41% 499,764 $6.9M
22 EVENTIDE ASSET MANAGEMENT, LLC 0.35% 1,513,958 $21.0M
23 DRIEHAUS CAPITAL MANAGEMENT LLC 0.31% 2,987,147 $41.5M
24 Nantahala Capital Management, LLC 0.27% 535,684 $7.4M
25 Alpha Wave Global, LP 0.25% 142,336 $2.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — AMYLYX PHARMACEUTICALS INC (AMLX)

What does the Smart Money Trend signal show for AMLX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their AMLX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for AMLX?

Slight buying edge — 50% buying: Last quarter: 91 funds bought or added vs 90 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for AMLX holders?

Strong quality — 37% AUM from major funds: 39 of 171 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held AMLX?

43% of holders stayed for 2+ years: 73 out of 171 hedge funds have held AMLX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy AMYLYX PHARMACEUTICALS INC (AMLX) following the 2026 Q1 hedge fund 13F filings?

As of today, AMLX has moved -2.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.2% for the XLV sector ETF — an outperformance of -7.3%. Since the quarter end (March 31, 2026), AMLX has gained -6.0% vs +4.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →